ID :
573992
Fri, 08/21/2020 - 13:53
Auther :
Shortlink :
https://www.oananews.org//node/573992
The shortlink copeid
Malaysian Genomics Records Turnaround Net Profit To RM17.1 Mln
KUALA LUMPUR, Aug 21 (Bernama) -- Malaysian Genomics Resource Centre Bhd posted a net profit of RM17.1 million (US$4.09 million) for the financial year ended June 30, 2020 from a net loss of RM3.84 million, mainly due to a one-off gain from the sale of its pathology lab chain.
Revenue jumped 60.6 per cent to RM951,000 due to strengthening demand seen in its core genetic screening segment, after reflecting the disposal of pathology lab subsidiary MPath Group Sdn Bhd on Dec 24, 2019.
“We’ve a lot planned for our pipeline as part of our strategy to maintain this profitability. We’re looking to contribute towards further improvements in healthcare, starting with improving quality of life in the fight against cancer,” its chief operating officer, Sasha Nordin said in a statement.
In June, Malaysian Genomics announced the addition of companion diagnostics and cancer immunotherapy based on Chimeric Antigen Receptor T-cells to its portfolio of products and services in Southeast Asia.
He said the company would be among the first to offer such cutting-edge services in Southeast Asia.
“This new addition will enhance our portfolio of personalised healthcare products and services for doctors and medical centres in the region.
“In the longer run, we are looking to explore this area further by expanding our portfolio of immunotherapy products and services, and also identifying applications in market segments beyond oncology,” he added. (US$1 = RM4.17)
-- BERNAMA